Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.

Abstract

BACKGROUND:

LY2780301, a dual inhibitor of protein kinase B (AKT) and the downstream effector p70 ribosomal protein S6 kinase (p70S6K), may inhibit progression in tumours relying on phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling pathway activation. This phase IB trial investigated the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), safety, pharmacokinetics (PK) and antitumour activity of LY2780301 plus gemcitabine in patients with advanced/metastatic solid tumours.

METHODS:

This was a non-randomised, open-label, dose escalation and dose expansion trial. Patients harbouring molecular alterations of the PI3K/AKT/mTOR pathway received once daily (QD) oral LY2780301 (400 or 500 mg) in combination with intravenous gemcitabine (750 or 1000 mg/m2) on days 1, 8 and 15 of a 28-d cycle. Dose escalation followed a 3 + 3 design. Assessments included adverse events (AEs), PK and preliminary antitumour activity.

RESULTS:

Fifty patients (median age, 53 years; 74% female) predominantly with mutations/amplifications of PI3K (60%) and phosphatase and tensin homologue (PTEN) gene/protein inactivation (42%) were treated for up to 14 cycles. The MTD was LY2780301 500 mg QD with gemcitabine 750 mg/m2. DLTs during cycle 1 were grade IV thrombocytopenia, grade III skin rash and grade III increase in alkaline phosphatase, gamma glutamyltransferase and alanine aminotransferase, occurring in one patient each. Most common AEs were anaemia (84%), fatigue (84%), transaminase increase (74%), thrombocytopenia (74%), nausea/vomiting (70%), neutropenia (68%) and lymphopenia (56%). Among the efficacy-evaluable population, two patients (5%) had a partial response; the disease control rate was 74% at cycle 2.

CONCLUSIONS:

Addition of LY2780301 to gemcitabine showed manageable toxicity and encouraging antitumour activity in patients with molecular alterations of the PI3K/AKT/mTOR pathway.

CLINICAL TRIAL REGISTRATION NUMBER:

NCT02018874.

• Authors: Eric Angevin, Philippe A Cassier, Antoine Italiano, Anthony Gonçalves, Anas Gazzah, Catherine Terret, Maud Toulmonde, Gwenaëlle Gravis, Andrea Varga, Cédric Parlavecchio, Angelo Paci, Vianney Poinsignon, Jean-Charles Soria, Damien Drubay, Antoine Hollebecque
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 83 Pg. 194-202 (09 2017) ISSN: 1879-0852 [Electronic] England
• PMID: 28750271 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2017 Elsevier Ltd. All rights reserved.

Chemical References

• Antimetabolites, Antineoplastic
• Antineoplastic Agents
• Protein Kinase Inhibitors
• Deoxycytidine
• Proto-Oncogene Proteins c-akt
• Ribosomal Protein S6 Kinases, 70-kDa
• Gemcitabine

Topics

• Adult
• Aged
• Antimetabolites, Antineoplastic (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Dose-Response Relationship, Drug
• Humans
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Protein Kinase Inhibitors (administration & dosage, therapeutic use)
• Proto-Oncogene Proteins c-akt (antagonists & inhibitors)
• Ribosomal Protein S6 Kinases, 70-kDa (antagonists & inhibitors)
• Gemcitabine